VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
WGS
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
WGSGeneDx Holdings Corp.
$47.29$1.4B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksWGSCash Flow

GeneDx Holdings Corp. (WGS) Cash Flow Statement

6Y historyFree accessUpdated daily

Operating cash flow was -$10.6M and free cash flow was -$15.8M in Q3 2026, with a free cash flow margin of -12.9% that remains firmly negative, and no dividends or buybacks were recorded, so capital is being consumed rather than returned.

Income StatementBalance SheetCash FlowRatios

WGS Cash Flow Statement

Annual statement

WGS Cash Flow Statement

GeneDx Holdings Corp. (WGS) cash flow statement — 6-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20
Cash from Operations-75.08M33.28M-28.5M-180.15M-319.15M-190.43M-93.13M
Operating CF Margin %-7.78%-9.33%-88.93%-135.99%-89.74%-51.93%
Operating CF Growth %-960.72%216.78%84.18%43.55%-67.59%-104.49%-
Net Income-111.05M-21.02M-52.29M-175.77M-548.98M-245.39M-241.34M
Depreciation & Amortization27.3M25.22M21.95M33.73M59.31M21.81M11.73M
Stock-Based Compensation33.37M32.16M9.14M-326K41.98M219.42M120.23M
Deferred Taxes-43K0-343K-926K-49.12M00
Other Non-Cash Items35.78M12.51M17.79M1.38M141.53M-194.35M2.4M
Working Capital Changes-60.44M-15.6M-24.75M-38.24M36.13M8.08M13.85M
Change in Receivables-31.41M-36.23M-5.42M10.26M5.53M5.54M-10.61M
Change in Inventory-11.19M-3.44M-2.58M975K4.6M-10.62M-8.98M
Change in Payables-12.39M12.1M-20.46M-46.95M34.46M00
Cash from Investing-41.38M-61.52M-30.13M-43.73M-141.33M-20.79M-31.97M
Capital Expenditures-26.14M-19.02M-5.49M-5.71M-14.32M-9.4M-24.09M
CapEx % of Revenue5.67%4.45%1.8%2.82%6.1%4.43%13.44%
Acquisitions-32.86M-32.86M0-8.11M-127M00
Investments-------
Other Investing33.2M0000-11.39M-7.88M
Cash from Financing116.63M48.02M44.16M186.24M197.31M493.73M129.06M
Debt Issued (Net)89.09M-3.66M-3.23M42.95M-3.29M-13.47M11.73M
Equity Issued (Net)-20.24M51.69M46.5M143M197.66M442.68M117.32M
Dividends Paid0000000
Share Repurchases0000000
Other Financing47.78M0891K285K2.95M64.51M0
Net Change in Cash174K19.79M-14.47M-37.72M-263.17M282.51M3.95M
Free Cash Flow-101.22M14.26M-33.99M-185.86M-333.48M-211.22M-125.1M
FCF Margin %-21.97%3.34%-11.13%-91.75%-142.09%-99.54%-69.76%
FCF Growth %-754.44%141.96%81.71%44.27%-57.88%-68.84%-
FCF per Share-3.390.53-1.26-7.64-32.58-64.49-22.23
FCF Conversion (FCF/Net Income)0.91x-1.58x0.55x1.02x0.58x0.78x0.39x
Interest Paid-222K6.41M6.68M3.04M1.93M2.75M1.75M
Taxes Paid-112K1.27M1.17M1.47M1.24M349K0

Key Metrics

Growth RegimeMixed
ProfitabilityWeak
Balance SheetAdequate
Cash FlowMixed
Top Statement Risk

Persistent operating cash burn

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Operating Cash Flow Tracks Losses Inconsistently

Based on reported quarterly figures, WGS posted a Q1 2026 net loss of -$63.3M against operating cash outflow of -$32.4M, yielding an OCF-to-net-income ratio of 0.51 that suggests non-cash charges absorbed part of the loss.

The gap between net income and operating cash flow is the central signal in this dataset, and it fluctuates sharply, with ratios ranging from 0.15 to over 1.6 across recent quarters. Such instability suggests that earnings are heavily influenced by non-cash and timing items rather than steady cash generation. Investors should monitor whether the positive ratio in Q3 2026 reflects genuine conversion improvement or merely a temporary working capital reversal.

Free Cash Flow Remains Deeply Negative

As reported in the cash flow statements, WGS's free cash flow margin reached -38.0% in Q1 2026 and -34.2% in Q2 2026, with only a modest improvement to -12.9% in Q3 2026 that remains firmly negative.

Free cash flow has been negative in most recent periods, with only brief positive stretches in 2025 that were not sustained. The latest quarter's narrower burn appears encouraging, but it still sits well below breakeven and does not yet demonstrate a durable turn. The trajectory warrants further investigation to determine whether margin repair can outpace continued working capital drag.

Working Capital Drag Drives Cash Volatility

Based on reported figures, working capital absorbed roughly -$23.2M in Q1 2026 and -$22.6M in Q2 2026, indicating that receivables and timing effects contributed materially to operating cash outflows during the period.

Working capital swings appear to be a dominant driver of quarterly operating cash flow, often exceeding the magnitude of underlying operating results. This pattern is consistent with revenue recognition dynamics such as implicit price concessions and prior-period true-ups noted in the business profile, which may delay cash collection from payers. Investors should monitor collection cycles, as sustained working capital consumption could keep cash needs elevated even if reported revenue continues to grow.

Light Capital Intensity Limits Investment Burden

According to quarterly disclosures, WGS's capital expenditures ran between 0.8% and 8.8% of revenue over the period, with the Q2 2026 peak of -$10.1M representing the most significant infrastructure outlay.

Capital spending is modest relative to revenue, suggesting the laboratory footprint does not currently demand heavy reinvestment. The fluctuation in capex intensity may reflect lumpy equipment purchases rather than a steady maintenance baseline. Because the company is not yet cash-flow positive, even this moderate spending adds to the funding need, and the mix between maintenance and growth capex remains undisclosed in the supplied data.

No Shareholder Returns Amid Cash Burn

Based on reported figures, WGS recorded no dividends or share repurchases across all ten quarters, with acquisition outflows appearing only once at -$32.9M in Q4 2025, indicating capital has been retained rather than returned.

The absence of distributions is consistent with a company still funding operating losses and working capital needs from its existing liquidity base. The single acquisition-related outflow in late 2025 coincides with the restructuring period described in the business profile and warrants scrutiny of its strategic purpose. Investors should monitor whether future cash deployment prioritizes balance sheet preservation or renewed investment in the data platform.

Cash Burn Masked by Non-Cash Add-Backs

Based on reported figures, stock-based compensation of $8.3M in Q3 2026 and $6.3M in Q2 2026 is a non-cash add-back that may flatter reported operating cash flow, warranting adjustment before judging the true cash burn rate.

Because SBC is excluded from operating cash outflows, the headline OCF figures overstate economic cash generation to the extent equity compensation substitutes for cash wages. The quarterly D&A of roughly $6.5M to $7.0M also cushions reported operating results without reflecting any replacement capital required for the laboratory asset base. Investors should monitor whether the Q3 2026 improvement is sustained once these non-cash items and the implied fourth-quarter guidance step-up are scrutinized.

WGS — Frequently Asked Questions

Quick answers to the most common questions about buying WGS stock.

How much cash does GeneDx Holdings Corp. (WGS) generate from operations?

GeneDx Holdings Corp. (WGS) generated $33.3M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is GeneDx Holdings Corp.'s free cash flow?

GeneDx Holdings Corp. (WGS) generated $14.3M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is GeneDx Holdings Corp.'s capital expenditure (CapEx)?

GeneDx Holdings Corp. (WGS) spent $19.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.